NovoCure (NVCR) EBT Margin Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -305.00 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -9.00 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -222.00 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 923.00 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -480.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2,114.00 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 1,391.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -176.00 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 329.00 |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | 202.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 202.00 |
| Dec 31, 2025 | 186.00 |
| Sep 30, 2025 | -8.00 |
| Jun 30, 2025 | -545.00 |
| Mar 31, 2025 | -1,772.00 |
| Dec 31, 2024 | -1,504.00 |
| Sep 30, 2024 | -603.00 |
| Jun 30, 2024 | -520.00 |
| Mar 31, 2024 | -2,082.00 |
| Dec 31, 2023 | -3,493.00 |
| Sep 30, 2023 | -4,620.00 |
| Jun 30, 2023 | -4,626.00 |
| Mar 31, 2023 | -3,610.00 |
| Dec 31, 2022 | -2,375.00 |
| Sep 30, 2022 | -1,929.00 |
| Jun 30, 2022 | -1,653.00 |
| Mar 31, 2022 | 975.00 |
| Dec 31, 2021 | -366.00 |
| Sep 30, 2021 | 392.00 |
| Jun 30, 2021 | 625.00 |
| Mar 31, 2021 | 3,160.00 |
| Dec 31, 2020 | 1,897.00 |
| Sep 30, 2020 | 2,444.00 |
| Jun 30, 2020 | 4,965.00 |
| Mar 31, 2020 | 3,964.00 |
| Dec 31, 2019 | -20,080.00 |
| Sep 30, 2019 | 14,192.00 |
| Jun 30, 2019 | 21,086.00 |
| Mar 31, 2019 | 23,731.00 |
| Dec 31, 2018 | 23,868.00 |
| Sep 30, 2018 | 26,796.00 |
| Jun 30, 2018 | 41,302.00 |
| Mar 31, 2018 | 39,911.00 |
| Dec 31, 2017 | -93,952.00 |
| Sep 30, 2017 | 39,445.00 |